What Can You Expect from Europe’s Obesity Drug Development Summit?
Join the inaugural Obesity Drug Development Summit Europe—the definitive forum for pharmaceutical leaders, biotech innovators, and academic pioneers driving the next wave of metabolic therapies.
From the 1st to 2nd October 2025 in Barcelona, this summit will unite 50+ industry experts to tackle critical challenges in obesity drug development, from novel targets and clinical trial design to manufacturing breakthroughs and payer strategies. Whether you’re exploring GLP-1 combinations, RNA-based platforms, or real-world evidence, this is your chance to shape the future of a $100 billion market.

Unmissable Event Highlights
We have handpicked some of the key topic on this year's agenda all to help you advance next-generation obesity therapies to patients faster.
Unlock Next-Gen Targets
Dive into pioneering research on GIPR modulators, mitochondrial activators, and DNA-encoded therapies to transform metabolic outcomes.
Optimise Clinical Trials
Learn to leverage biomarkers, precision dosing, and patient-centric endpoints for faster approvals and reimbursement.
Master Combination Therapies
Discover strategies to preserve lean mass and enhance efficacy with GLP-1/myostatin-amylin combos.
Exclusive Networking
Connect with 50+ decision-makers from Novo Nordisk, Eli Lilly, and Boehringer Ingelheim during curated sessions.
Navigate Manufacturing Challenges
Gain insights into oral formulations and extended-release injectables to overcome production bottlenecks.
Attending Companies Include








